Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles

Human Vaccines

Volumn 4, Issue 1, 2008, Pages 23-30

  Finney, Michelle ^a   Vaughan, Thomas ^a   Taylor, Stephen ^a   Hudson, Michael J ^a   Pratt, Catherine ^a   Wheeler, Jun X ^b   Vipond, Caroline ^b   Feavers, Ian ^b   Jones, Christopher ^b   Findlow, Jamie ^a   Borrow, Ray ^a   Gorringe, Andrew ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Meningococcal disease; Neisseria lactamica; Outer membrane vesicles; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; BACTERIAL PROTEIN; MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGENICITY; ARTICLE; BACTERIAL GENOME; BACTERIAL OUTER MEMBRANE; BACTERICIDAL ACTIVITY; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE RESPONSE; IMMUNOGENICITY; MASS SPECTROMETRY; MEMBRANE VESICLE; MENINGOCOCCOSIS; MOUSE; NEISSERIA; NEISSERIA LACTAMICA; NEISSERIA MENINGITIDIS; NONHUMAN; OPSONIZATION; PHAGOCYTOSIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; RABBIT; VACCINE PRODUCTION; WESTERN BLOTTING;

EID: 44649137353     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.4.1.4806     Document Type: Article

References (36)

1. Rosenstein NE, Bradley A, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Eng J Med 2001; 344:1378-88.
2. WHO position paper: Meningococcal vaccines: Polysaccharide and polysaccharide conjugate vaccines. WHO position paper: Weekly Epidemiological Record 2002; 77:331-9.
3. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunization campaign against meningococcal serogroup C disease in the UK: A success story. Vaccine 2001; 20:S58-67.
4. Gray SJ, Trotter CL, Ramsey ME, Guiver M, Fox AJ, Borrow R, Mallard RH, Kaczmarski EB. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: Contribution and experiences of the meningococcal Reference Unit. J Med Microbiol 2006; 55:887-96.
5. Finne J. Occurrence of unique polysialosyl carbohydrate units in glycoproteins of the developing brain. J Biol Chem 1982; 257:11966-70.
6. Sierra GV, Campa HC, Varcacel NM, Garcia IL, Izquierdo PL, Sotolongo PF, Casanueva GV, Rico CO, Rodrýguez CR, Terry MH. Vaccine against group B Neisseria meningitidis: Protection trial and mass vaccination results in Cuba. NIPH Ann 1991; 14:195-207.
7. Cassio de Moraes J, Perkins BA, Camargo MCC, Rossetto Hidalgo NT, Aparecida Barbosa H, Tavares Sacchi C, Land Gral IM, Gattas VL, Vasconcelos HG, Plikaytis BD, Wenger JD, Broom CV. Protective efficacy of a serogroup b meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992; 340:1074-8.
8. Bjune G, Høiby EA, Grønnesby JK, Arnesen Ø, Fredriksen JH, Halstensen A, Holten E, Lindbak AK, Nøkleby H, Rosenqvist E, Solberg LK, Closs O, Eng J, Frøholm LO, Lystad A, Bakketeig LS, Hareide B. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991; 338:1093-6.
9. Thornton V, Lennon D, Rasanathan K, O'Hallahan J, Oster P, Stewart J, Tilman S, Aaberge I, Feiring B, Nøkleby H, Rosenqvist E, White K, Reid S, Mulholland K, Wakefield MJ, Martin D. Safecy and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: Beginning of epidemic control. Vaccine 2006; 24:1395-400.
10. Feavers IM, Fox AJ, Gray S, Jones DM, Maiden MC. Antigenic diversity of meningococcal outer membrane protein PorA has implications for epidemiological analysis and vaccine design. Clin Diagn Lab Immunol 1996; 3:444-50.
11. Gold R, Goldschneider I, Lepow ML, Draper TF, Randolph M. Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children. J Infect Dis 1978; 137:112-21.
12. Gorringe A. Can Neisseria lactamica antigens provide an effective vaccine to prevent meningococcal disease? Expert Rev Vaccines 2005; 4:373-9.
13. Pollard AJ, Frasch C. Development of natural immunity to Neisseria meningitidis. Vaccine 2001; 19:1327-46.
14. Bennett JS, Griffiths DT, McCarthy ND, Sleeman KL, Jolley KA, Crook DW, Maiden MCJ. Genetic diversity and carriage dynamics of Neisseria lactamica in infants. Infect Immun 2005; 73:2424-32.
15. Oliver KJ, Reddin KM, Bracegirdle P, Hudson MJ, Borrow R, Feavers IM, Robinson A, Cartwright K, Gorringe AR. Neisseria lactamica protects against experimental meningococcal infection. Infect Immun 2002; 70:3621-6.
16. Gorringe A, Halliwell D, Matheson M, Reddin K, Finney M, Hudson M. The development of a meningococal disease vaccine based on Neisseria lactamica. Vaccine 2005; 23:2210-3.
17. In: Jolley KA, ed. Full Information on Strain Y92-1009: The Neisseria PubMLST Database. (http://pubmlst.org/perl/mlstdbnet/mlstdbnet.pl?page= straininfo&file=pub-nm_isolates. xml&id=4945).
18. Kaczmarski EB, Birtles A, Guiver M, Newbold L, Gray S, Carr T, Mallard R. Non-culture based characterization of Neisseria meningitidis to guide public health interventions and vaccine development, Federation of Infection Societies Seventh Conference, Manchester, United Kingdom. 2003.
19. Frasch CE, van Alphen L, Holst J, Poolman JT, Rosenqvist E. Outer membrane protein vesicle vaccines for meningococcal disease. In: Pollard AJ, Maiden MC, eds. Meningococcal Vaccines: Methods and Protocols. Totawa, NJ: Humana Press, 2001:81-107.
20. Vipond C, Wheeler JX, Jones C, Feavers IM, Suker J. Characterization of the protein content of a meningococcal outer membrane vesicle vaccine by polyacrylamide gel electrophoresis and mass spectrometry. Human Vaccines 2005; 1:80-4.
21. Vaughan TE, Skipp PJ, O'Connor CD, Vipond R, Elmore MJ, Gorringe AR. Proteomic analysis of Neisseria lactamica and Neisseria meningitidis outer membrane vesicle vaccine antigens. Vaccine 2006; 24:5277-93.
22. Findlow J, Taylor S, Aase A, Horton R, Heyderman R, Southern J, Andrews N, Barchha R, Harrison E, Lowe A, Boxer A, Heaton C, Balmer P, Kaczmarski E, Oster P, Gorringe A, Borrow R, Miller E. Comparison and correlation of Neisseria meningitidis serogroup immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac. Infect Immun 2006; 74:4557-65.
23. Loferer H, Hammar M, Normark S. Availability of the fibre subunit CsgA and the nucleator protein CsgB during assembly of fibronectin-binding curli is limited by the intracellular concentration of the novel lipoprotein CsgG. Mol Microbiol 1997; 26:11-23.
24. Vipond C, Suker J, Jones C, Tang C, Feavers IM, Wheeler JX. Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98/254. Proteomics 2006; 11:3400-13.
25. Norheim G, Aase A, Caugant DA, Høiby EA, Fritzsønn E, Tangen T, Kristiansen P, Heggelund U, Rosenqvist E. Development and characterization of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis. Vaccine 2005; 23:3762-74.
26. Kim JJ, Mandrell RE, Griffiss JM. Neisseria lactamica and Neisseria meningitidis share lipopolysaccharide epitopes but lack common capsular class 1, 2 and 3 protein epitopes. Infect Immun 1989; 2:602-8.
27. Morley SL, Pollard AJ. Vaccine prevention of meningococcal disease, coming soon? Vaccine 2001; 20:666-87.
28. Holst J, Feiring B, Fuglesang JE, Høiby EA, Nøkleby H, Aaberge IS, Rosenqvist E. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 2003; 21:734-7.
29. Li Y, Zhang Q, Winterbotham M, Mowe E, Gorringe A, Tang CM. Immunization with live Neisseria lactamica protects mice against meningococcal challenge and can elicit serum bactericidal antibodies. Infect Immun 2006; 74:6348-55.
30. O'Dwyer CA, Reddin K, Martin D, Taylor SC, Gorringe AR, Hudson MJ, Brodeur BR, Langford PR, Kroll JS. Expression of heterologous antigens in commensal Neisseria spp.: Preservation of conformational epitopes with vaccine potential. Infect Immun 2004; 72:6511-8.
31. Tappero JW, Lagos R, Ballesteros AM, Plikaytis B, Williams D, Dykes J, Gheesling LL, Carlone GM, Høiby EA, Holst J, Nøkleby H, Rosenqvist E, Sierra G, Campa C, Sotolongo F, Vega J, Garcia J, Herrera P, Poolman JT, Perkins BA. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: A randomized controlled trial in Chile. JAMA 1999; 281:1520-7.
32. Martin SL, Borrow R, van der Ley P, Dawson M, Fox AJ, Cartwright KA. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine. Vaccine 2000; 18:2476-81.
33. Findlow J, Lowe A, Deane S, Balmer P, van den Dobbelsteen G, Dawson M, Andrews N, Borrow R. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine in toddlers and school children. Vaccine 2005; 23:2623-7.
34. O'Hallahan J, Lennon D, Oster P. The strategy to control New Zealand's epidemic of group B meningococcal disease. Pediatr Infect Dis J 2004; 23:293-8.
35. Holst J, Feiring B, Naess LM, Norheim G, Kristiansen P Høiby EA, Bryn K, Oster P, Costantino P, Taha MK, Alonso JM, Caugant DA, Wedege E, Aaberge IS, Rappuoli R, Rosenqvist E. The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine 2005; 23:2202-05.
36. Halperin SA, Langley JM, Smith B, Wunderli P, Kaufman L, Kimura A, Martin D. Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults. Vaccine 2007; 25:450-7.